MedPath

Study of large intestine in retention of faeces in relation with fecal calprotecti

Phase 2
Not yet recruiting
Conditions
Health Condition 1: K638- Other specified diseases of intestine
Registration Number
CTRI/2022/12/048079
Lead Sponsor
Dr Sachin Rangrao Patil
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Selected 120 diagnosed patients of purishaja udavarta

Exclusion Criteria

Patients below 40 years and above 60 yearsAvirecya

Patients taken non-steroidal anti-inflammatory drugs.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Assessment of pakvashaya is possible on the basis of investigation range of fecal calprotectinTimepoint: 3 weeks
Secondary Outcome Measures
NameTimeMethod
1.Relieving of Mala sang and reduction in sign and symptoms of purishaja udavarta vyadhi <br/ ><br>2.Effect of Eranda taila on gut biomarkersTimepoint: 3 weeks
© Copyright 2025. All Rights Reserved by MedPath